行情

AIKI

AIKI

AIkido Pharma
NASDAQ

实时行情|Nasdaq Last Sale

0.7300
-0.0064
-0.87%
已收盘, 19:57 09/21 EDT
开盘
0.7270
昨收
0.7364
最高
0.7400
最低
0.7230
成交量
45.41万
成交额
--
52周最高
2.550
52周最低
0.4656
市值
6,546.72万
市盈率(TTM)
-5.6502
分时
5日
1月
3月
1年
5年
简报-合气道制药公司获得了对不断发展的远程健康公司的兴趣
reuters.com · 1天前
合气道收购远程医疗公司 Kerna Health 的股份;分享下来
MT Newswires · 1天前
合气道制药发布股东更新(正文全文)
Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start,
Benzinga · 09/14 13:24
合气道制药提供关于在药物开发计划中使用机器学习的最新消息:“该项目的目标是识别和优化抗病毒化合物,通过靶向降解 RNA 的蛋白质复合物来抑制病毒复制......
AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided and update on the use of Machine Learning in support of its antiviral platform with the University of Maryland Baltimore
Benzinga · 08/06 14:02
合气道提供机器学习在药物开发计划中使用的最新信息
/PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided and update on the use of Machine Learning in support of its antiviral platform with the School of Medicine.  The Company stated: 
PR Newswire - PRF · 08/06 14:00
中枢神经系统多肽技术获批通知
/PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/477,125.  This technology relates to the use of novel and propr...
PR Newswire - PRF · 07/27 14:00
医疗保健行业的 5 只价值股
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most lik...
Benzinga · 07/26 14:24
合气道制药与马里兰大学发布抗病毒平台更新
AIkido Pharma ([[AIKI]] -0.8%) provided an update to the progress of its antiviral platform with the University of Maryland School of Medicine.As part of the project, scientists have identified 4
Seekingalpha · 07/16 14:23
更多
财务预测
暂无数据
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AIKI最新的财务预测,通过AIKI每股收益,每股净资产,每股现金流等数据分析AIkido Pharma近期的经营情况,然后做出明智的投资选择。
暂无数据
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.43%
制药与医学研究
+0.74%
高管信息
Non-Executive Chairman/Independent Director
Robert Vander Zanden
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Director
Anthony Hayes
Director
Robert Dudley
Director
Paul LeMire
Director
Kyle Wool
Independent Director
Gregory Blattner
Independent Director
Tim Ledwick
暂无数据
AIKI 简况
Aikido Pharma Inc.是一家生物技术公司。该公司专注于开发各种小分子抗癌治疗药物。它的多种疗法包括胰腺癌、急性髓细胞性白血病(AML)和急性淋巴细胞性白血病(ALL)的疗法。此外,该公司一直在寻求扩大其渠道以治疗其在肿瘤学方面尚未满足的医疗需求。

微牛提供Aikido Pharma Inc(NASDAQ-AIKI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AIKI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AIKI股票基本功能。